This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. tetrahydrocannabinol (THC).
Florida medical marijuana doctors are recommending medical marijuana for anxiety, depression and many other mental health conditions. Anxiety is one aspect of a broader condition- anxiety disorder. The authors conclude that: Mental health conditions are prominent among the reasons for medical cannabis use.
According to a 2017 report published by the National Academies of Sciences , PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. When the body is defensive against trauma, this system begins to fail, resulting in physical, mental and/or neurological conditions.
In 2017, The National Academies of Sciences, Engineering, and Medicine published a statement that the use of cannabis for the treatment of pain is supported by “well-controlled clinicaltrials and that there is substantial evidence that cannabis is an effective treatment for chronic pain in adults.”.
Cann Group CEO Peter Crock said of the products: “Satipharm CBD capsules were one of the first medicinal cannabis products available to approved patients in Australia (under the Special Access Scheme) and have been successfully used in a variety of medical conditions since 2017.
Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. More than 80% of survey respondents indicated strong interest in learning more information about a clinicaltrial, and more than half were interested in enrolling in a clinicaltrial.
Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. tetrahydrocannabinol (THC).
In addition, data from the 2017 National Survey on Drug Use and Health showed a potential inverse relationship between marijuana and opioid use, based on data that reported a drop of opioid misuse from 2016 to 2017 (from 11.8 million to 11.4
We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinicaltrial under an FDA IND approval.” ” Next Steps.
Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. The respondents ranged in age from 19 to 81, and 50% identified as White, 20% as Latino, 12% as Asian, and 10% as Black.
It turns out that this blissful drug, MDMA, has the potential to be used effectively as a treatment for certain conditions- some of which are in urgent need of effective medical assistance. . MDMA has also reportedly been used with over 1,000 individuals in clinicaltrials , with no adverse effects to report. . What is MDMA?
According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions.
CBD first appeared on the natural channel’s top 40 list in 2017, ranking 12th, after sales growth of more than 300% from the previous year. million more on CBD products in 2021 compared to 2017 — a 413.4% Despite its top rank in 2021, sales of this ingredient have slowed in recent years. Consumers spent roughly $31.3
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinicaltrials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , ClinicalTrial ID NCT03866174, available at [link].
Examples include pneumonia, cancers, tuberculosis, chronic diarrhea, and inflammation-based conditions such as meningitis and encephalitis. Depending on what type of cell it is, but also the type of condition a person is struggling with, these factors determine the way how will a specific cell react to cannabinoids.
The study by researchers from the University of Auckland and medical cannabis clinic owner Dr Graham Gulbransen looked at how patients were faring after using cannabidiol (CBD), the non-intoxicating compound in cannabis that has had so much attention these past few years. reported a worsening of a pre-existing condition.
Drug interactions reported in the scientific literature most often occur at very high doses used in clinicaltrials of epilepsy and other conditions. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. . The Journal of Clinical Pharmacology 60.4
For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. Clinicaltrials are also underway to determine the possibility of THC, cannabis, and other cannabinoids to help with obesity and appetite. That’s why some people choose THC oil. THC Oil Effects.
World Drug Report ‘s estimation that 18 million people between 15 and 64 years of age consumed cocaine in 2017. Note: No human studies were found (with the exception of one clinicaltrial that was ongoing and therefore not selected); all studies focused on animals (i.e., Conditioned place preference. mice/rats).
One such breakthrough in research came back in 2017, when researchers found strong evidence that cannabis could help treat dementia. Now, clinical studies are about to get underway at an Australia university, to track changes in actual dementia patients to see if cannabis can help. But in recent years, new research both in the U.S.
Over the years, research has generated results to suggest that marijuana benefits in the treatment of some conditions. The drug for treating such conditions involves a purified form of CBD. The approval is based on the research and clinicaltrials. Let us have a look at those. Chronic pain. CBD occurs in cannabis.
A 2017 review of 10 clinicaltrials found that people who took probiotics had a 14% lower risk of contracting a cold or flu. Probiotics have been found to be useful in treating or preventing a number of conditions, including: Digestive disorders (such as inflammatory bowel disease). Probiotics May Reduce Flu Risk.
Lack of clinicaltrials is a major reason why doctors are cautious about the drug. In January 2017, the German Parliament passed a reform of the country’s drug law, allowing easier access to cannabis products for therapeutic purposes. Before the law was changed, only 1,000 patients were prescribed with medical cannabis.
The Victorian and New South Wales Governments had both begun clinicaltrials of cannabis products for children with severe epilepsy and for palliative care, respectively. The clinicaltrials and the standard of production could lead the world.”.
For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. to take a medical marijuana course that reviews the endocannabinoid system and the therapeutic use of marijuana.
deletion syndrome clinicaltrial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The trial is currently registered with the Australian New Zealand ClinicalTrials Registry (ANZCTR).
Drug interactions reported in the scientific literature most often occur at very high doses used in clinicaltrials of epilepsy and other conditions.[1]. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. [2]. The Journal of Clinical Pharmacology 60.4
As yet there have been no FDA -approved clinicaltrials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”.
However, we firmly disagree that the referenced clinicaltrials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited.
However, many customers, new medical cannabis customers are going into the dispensary with a note from their doctor saying you qualify under one of the state conditions that enable you to use cannabis. That is a medical condition. But the doctor isn’t giving the patient any guidance. But what do we do in the meantime?
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinicaltrials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. IMAJ, FEBRUARY 2017.
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Spasticity from neurological conditions. Background. Conclusions. Bonini et al.
A systematic review published in 2017 aimed to identify available data about the therapeutic effect of cannabinoids treatment in children and adolescents. Therefore, a summary table of adverse mental events is presented with Conditional maximum likelihood estimate of Rate Ratio and Fischer exact test 46. Results.
As yet there have been no FDA -approved clinicaltrials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”.
The accident also reactivated a pre-existing psychological condition which manifested as a chronic pain syndrome, and a pre-existing depressive disorder which was in partial remission at the time of trial. Ahn , 2016 BCSC 795, reversed on other grounds 2017 BCCA 221. Mistry , 2017 BCSC 239. Tower , 2017 BCSC 2068.
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinicaltrials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.
Depression can be situational, but Clinical Depression, which comes and goes and/or lasts for more than a few days, is a chemical imbalance within the central nervous system. Depression can make these conditions worse and vice versa. The NIMH states that women are often more affected by Depression than men.
In a systematic review published in 2017 , researchers found that “Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Clinicaltrials and placebo-controlled studies are needed to confirm the findings found in this review.
In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD. As previously mentioned, clinical studies are promising, including a Phase 3 trial (the last step before submitting an NDA) completed last November. [9] ClinicalTrials and Human Subject Protections. Approval Pathways.
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinicaltrial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinicaltrial results confirmed more than 80% of dogs showed significant or dramatic improvement.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content